Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in Sanandaj hospitals: a retrospective cohort study
Asadi et al.
, Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in Sanandaj hospitals: a..
, Journal of Pharmaceutical Policy and Practice, doi:10.1186/s40545-023-00511-w
Retrospective 660 hospitalized patients in Iran comparing 6 different drug regimens: 1. HCQ or CQ+AZ, 2. interferons (ReciGen/Ziphron) or interferon + Kaletra (lopinavir/ritonavir), 3. atazanavir, 4. remdesivir, 5. favipiravir, and 6. corticosteroids (dexamethasone/methylprednisolone).
Results show lower risk for HCQ/CQ+AZ in 20 of 25 comparisons (5 outcomes and 5 alternate regimens), with statistical significance in only two cases.
Asadi et al., 16 Jan 2023, retrospective, Iran, peer-reviewed, 7 authors, study period February 2020 - February 2021.
Abstract: Asadi et al.
Journal of Pharmaceutical Policy and Practice
Effectiveness of different treatment
regimens on patients with COVID‑19,
hospitalized in Sanandaj hospitals:
a retrospective cohort study
Jalal Asadi1, Mohammad Aziz Rasouli1,2, Ebrahim Ghaderi1,3, Daem Roshani1,3, Behzad Mohsenpour4,
Yousef Moradi3 and Ghobad Moradi1,3*
Objectives Different drugs have different effects on the prognosis of patients with COVID-19. This study aimed to
evaluate the effect of different drug regimens on patients with COVID-19, hospitalized in Sanandaj city.
Methods In this retrospective cohort study, 660 patients with COVID-19, hospitalized in the Tohid, Kowsar and Besat
hospitals located Sanandaj (Kurdistan Province, Iran) were studied from February 2020 to February 2021 with clinical
symptoms and positive test results.
Results The results of multivariate regression analysis showed the days of hospitalization for patients who had
received the drug regimen 2 (Interferons (ReciGen/Ziphron) or Interferon Vectra (lopinavir/ritonavir)) was 1.92 times
higher than those who had received the drug regimen 1 (hydroxychloroquine group or a combination of chloroquine
and azithromycin) while a significant association was observed (OR = 1.92, 95% CI: 1.16–3.16, P = 0.011). Also, the hospitalization in ICU was longer in patients treated by the drug regimen 2 (Interferons (ReciGen/Ziphron) or Interferon
Vectra (lopinavir/ritonavir)) (OR = 4.63, 95% CI: 1.80–11.82, P = 0.001), however, drug regimens did not show a significant effect on mortality and use of ventilator in patients (P > 0.05).
Conclusion The study results showed the drug regimens 2 and 5 increased the days of hospitalization and hospitalization in ICU, respectively, while the other drug regimens had no significant effect on mortality and use a ventilator in
the studied patients and none of the drug regimens had an effect on reducing mortality compared to other ones.
Keywords COVID-19, Drug regimen, Treatment, Retrospective cohort, Iran
Department of Epidemiology and Biostatistics, School of Medicine,
Kurdistan University of Medical Sciences, Sanandaj, Iran
Clinical Research Development Unit, Kowsar Hospital, Kurdistan
University of Medical Sciences, Sanandaj, Iran
Social Determinants of Health Research Center, Research Institute
for Health Development, Kurdistan University of Medical Sciences,
Department of Infectious Diseases, School of Medicine, Kurdistan
University of Medical Sciences, Sanandaj, Iran
The first case of COVID-19 was observed in a seafood
market in Wuhan, Hubei province, China on December 12, 2019, and the first positive case was diagnosed
21 days later, on January 3 in the United States [1, 2]. The
very high outbreak potential led to the announcement of
the COVID-19 global pandemic on March 11, 2020 .
The full range of COVID-19 disease is from a mild and
self-limiting respiratory disease to severe progressive
pneumonia, multiple organ failure, and death .
© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.